Where peptide leaders meet to build successful partnerships and accelerate products across all development phases
Increase half-life and minimise manufacturing costs through new data, case studies and technologies for peptide therapeutics
Lead optimisation strategies to improve drug-like properties for next generation peptide therapeutics
- Peptide therapeutics beyond metabolic diseases
Where are the future opportunities?
- Overcome the challenges of translating early leads into the clinic - Zealand Pharma and Amgen provide successful lead optimisation and engineering insights
- New frontiers in peptide design– What are the latest developments in peptide vaccines, conjugates, macrocyclic and antimicrobial peptides?
- Increasing the half-life, targeting and stability of peptide products – What are the cutting edge methodologies to move to longer exposure times?
New techniques for improved administration of peptide products
- Preclinical and clinical developments of complex peptides – What are the most exciting products advancing through the clinic?
- Benchmark your clinical programmes with case studies insights from Bicycle Therapeutics and Polyphor
- Non-invasive delivery methods - What are the latest advances in orally bioavailable, transdermal and controlled release peptides?
- Formulation strategies – Which are the winning techniques and technologies for sustained release?
Latest developments in large scale peptide manufacturing to reduce cost of goods
- Optimising process development, CMC and large scale manufacturing - How are industry overcoming the challenges of peptide scale up and production?
- Solid phase synthesis – Which new coupling methods and linkers can improve manufacturing efficiency?
220+ Decision Makers
110+ Companies from the Oligonucleotide and Peptide Industry
65:35 Buyer: Seller Ratio
Increase half-life and minimise manufacturing costs through new data, case studies and technologies for peptide therapeutics
Lead optimisation strategies to improve drug-like properties for next generation peptide therapeutics
- Peptide therapeutics beyond metabolic diseases
Where are the future opportunities?
- Overcome the challenges of translating early leads into the clinic - Zealand Pharma and Amgen provide successful lead optimisation and engineering insights
- New frontiers in peptide design– What are the latest developments in peptide vaccines, conjugates, macrocyclic and antimicrobial peptides?
- Increasing the half-life, targeting and stability of peptide products – What are the cutting edge methodologies to move to longer exposure times?
New techniques for improved administration of peptide products
- Preclinical and clinical developments of complex peptides – What are the most exciting products advancing through the clinic?
- Benchmark your clinical programmes with case studies insights from Bicycle Therapeutics and Polyphor
- Non-invasive delivery methods - What are the latest advances in orally bioavailable, transdermal and controlled release peptides?
- Formulation strategies – Which are the winning techniques and technologies for sustained release?
Latest developments in large scale peptide manufacturing to reduce cost of goods
- Optimising process development, CMC and large scale manufacturing - How are industry overcoming the challenges of peptide scale up and production?
- Solid phase synthesis – Which new coupling methods and linkers can improve manufacturing efficiency?
220+ Decision Makers
110+ Companies from the Oligonucleotide and Peptide Industry
65:35 Buyer: Seller Ratio
